Page last updated: 2024-11-06

1-(2-pyridinyl)piperazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(2-pyridinyl)piperazine is a heterocyclic compound with a piperazine ring attached to a pyridine ring. It has been reported to exhibit various pharmacological activities, including anti-inflammatory, anti-tumor, and anti-convulsant effects. The compound is often synthesized via a nucleophilic substitution reaction between 2-chloropyridine and piperazine. Its importance lies in its potential applications in drug discovery and development. Researchers are studying its effects on different biological systems to explore its therapeutic potential. 1-(2-pyridinyl)piperazine has been shown to interact with various receptors and enzymes, which could contribute to its pharmacological activities.'

1-(2-pyridinyl)piperazine: metabolite of buspirone & gepirone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID94459
CHEMBL ID18094
SCHEMBL ID7900
MeSH IDM0148119

Synonyms (69)

Synonym
BIDD:GT0511
BB 0218368
34803-66-2
nsc137781
nsc-137781
1-(2-pyridyl)piperazine
piperazine, 1-(2-pyridinyl)-
nsc-26624
1-(2-pyridyl)piperazine, >=99%
1-(2-pyridyl)piperazine, 98%
1-pyridin-2-yl-piperazine
1-(pyridin-2-yl)piperazine
STK796767
BRD-K72135511-001-01-2
AKOS000266171
1-(2-pyridinyl)piperazine
CHEMBL18094 ,
P1033
2-(1-piperazinyl)pyridine
bdbm50026634
1-pyridin-2-ylpiperazine
A6107
2-(piperazin-1-yl)pyridine
2-pyridylpiperazine
nsc 137781
unii-5io1hzp7zn
5io1hzp7zn ,
einecs 252-220-3
n-pyridin-2-ylpiperazine
4-(2-pyridinyl)piperazine
FT-0605567
LF-0569
AB00623
AM62509
pyridinylpiperazine
SCHEMBL7900
pyridyl piperazine
1-pyridin-2-yl piperazine
1-(2-pyridyl) piperizine
n-(pyridin-2-yl)piperazine
2-piperazinylpyridine
1-(2-pyridyl)-piperazine
2-pyridyl-piperazine
4-pyridin-2-yl-piperazine
4-(2-pyridyl)piperazine
1-(2-pyridinyl)-piperazine
1-(pyridine-2-yl)piperazine
pyridylpiperazine
4-(pyridin-2-yl)-piperazine
(pyridin-2-yl)piperazine
1-(pyridin-2-yl)-piperazine
n-(2-pyridyl)piperazine
n-(2-pyridyl) piperazine
(2-pyridyl) piperazine
1-(2-pyridyl) piperazine
Q-102292
1-(2-pyridinyl)piperazine #
2-piperizinopyridine
F2169-0995
DTXSID90188341
mfcd00006216
CS-W001990
piperazine, 1-(2-pyridyl)-
Q7263585
SY012687
2-piperazinopyridine
EN300-18708
HY-W001990
Z89265780

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"3 l/kg), and half-life (1."( 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats.
Dockens, RC; Grace, JE; Li, YW; Pajor, L; Stark, AD; Taub, RA; Wong, H; Yeola, S; Yocca, FD; Zaczek, RC, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
" Bioavailability was higher for 6-OH-buspirone (19%) compared with that for buspirone (1."( 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats.
Dockens, RC; Grace, JE; Li, YW; Pajor, L; Stark, AD; Taub, RA; Wong, H; Yeola, S; Yocca, FD; Zaczek, RC, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" Oral dosing of buspirone in rats resulted in exposures (area under the concentration-time profile) of 6-OH-buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP), another major metabolite of buspirone, that were approximately 12 (6-OH-buspirone)- and 49 (1-PP)-fold higher than the exposure of the parent compound."( 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats.
Dockens, RC; Grace, JE; Li, YW; Pajor, L; Stark, AD; Taub, RA; Wong, H; Yeola, S; Yocca, FD; Zaczek, RC, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phospholipase D1Homo sapiens (human)IC50 (µMol)3.60000.00101.06568.5000AID349537
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Kd1.99530.00020.52667.5858AID35872
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Kd0.39810.00020.62779.3325AID35476
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Kd0.39810.00020.62779.3325AID35476
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Kd0.39810.00020.62779.3325AID35476
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Kd1.99530.00020.89627.5858AID35872
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Kd1.99530.00020.51397.5858AID35872
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
phosphatidic acid biosynthetic processPhospholipase D1Homo sapiens (human)
chemotaxisPhospholipase D1Homo sapiens (human)
small GTPase-mediated signal transductionPhospholipase D1Homo sapiens (human)
Ras protein signal transductionPhospholipase D1Homo sapiens (human)
cellular response to nutrientPhospholipase D1Homo sapiens (human)
regulation of microvillus assemblyPhospholipase D1Homo sapiens (human)
positive regulation of translationPhospholipase D1Homo sapiens (human)
regulation of synaptic vesicle cyclePhospholipase D1Homo sapiens (human)
phospholipid catabolic processPhospholipase D1Homo sapiens (human)
regulation of vesicle-mediated transportPhospholipase D1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
phospholipase D activityPhospholipase D1Homo sapiens (human)
protein bindingPhospholipase D1Homo sapiens (human)
phosphatidylinositol bindingPhospholipase D1Homo sapiens (human)
N-acylphosphatidylethanolamine-specific phospholipase D activityPhospholipase D1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
cholinergic synapsePhospholipase D1Homo sapiens (human)
Golgi membranePhospholipase D1Homo sapiens (human)
lysosomal membranePhospholipase D1Homo sapiens (human)
endosomePhospholipase D1Homo sapiens (human)
endoplasmic reticulum membranePhospholipase D1Homo sapiens (human)
Golgi apparatusPhospholipase D1Homo sapiens (human)
plasma membranePhospholipase D1Homo sapiens (human)
membranePhospholipase D1Homo sapiens (human)
apical plasma membranePhospholipase D1Homo sapiens (human)
endocytic vesiclePhospholipase D1Homo sapiens (human)
late endosome membranePhospholipase D1Homo sapiens (human)
specific granule membranePhospholipase D1Homo sapiens (human)
perinuclear region of cytoplasmPhospholipase D1Homo sapiens (human)
tertiary granule membranePhospholipase D1Homo sapiens (human)
intracellular membrane-bounded organellePhospholipase D1Homo sapiens (human)
plasma membrane regionPhospholipase D1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID233671Selectivity ratio for alpha-2 adrenoceptor over alpha1 adrenoceptor of rat vas deferens1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID35865Antagonistic activity upon postsynaptic alpha-1 adrenergic receptor was determined in the rat isolated, field stimulated vas deferens using methoxamine1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
AID36648Antagonistic activity against central alpha-2 adrenergic receptor, in anesthetized rats (reversal of clonidine-induced mydriasis)1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID35476Presynaptic antagonistic activity against alpha-2 adrenergic receptor from rat, isolated, field-stimulated vas deferens, using clonidine as the agonist1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID349537Inhibition of PLD1 in human Calu1 cells2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity.
AID35872Presynaptic antagonistic activity against alpha-1 adrenergic receptor from rat, isolated, field-stimulated vas deferens, using methoxamine as the agonist1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID35362Antagonistic activity against clonidine-stimulated rat vas deferens presynaptic alpha-2 adrenergic receptor1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
AID35963Binding activity against alpha-1 adrenergic receptor from calf cerebral cortex, using [3H]-prazosin as the radioligand1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID409883Cytotoxicity against human HCT116 cells at 50 uM after 48 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID35907Displacement of [3H]clonidine from calf cerebral cortex alpha-2 adrenergic receptor1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
AID409884Cytotoxicity against human KMS11 cells at 50 uM after 48 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID409880Cytotoxicity against human HCT116 cells at 50 uM after 24 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID409882Cytotoxicity against human GBM cells at 50 uM after 48 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID35902Binding activity against alpha-2 adrenergic receptor from calf cerebral cortex, using [3H]clonidine as the radioligand1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID1267460Inhibition of recombinant N-terminal truncated human cytosolic 5'-nucleotidase-2 assessed as inhibition of inosine 5'-monophosphate hydrolysis at 1 mM by rapid green malachite assay2015Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24
Identification of Noncompetitive Inhibitors of Cytosolic 5'-Nucleotidase II Using a Fragment-Based Approach.
AID409881Cytotoxicity against human KMS11 cells at 50 uM after 24 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID233670Selectivity ratio of compound towards alpha-2 adrenoceptor over alpha1 adrenoceptor of calf cerebral cortex1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID233276Relative binding to alpha-1a and alpha-2 adrenergic receptors (ratio of Ki-prazosin and Ki-clonidine)1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
AID233275Selectivity ratio expressed as the ratio of -log methoxamine pA2 to -log clonidine pA21984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
AID781327pKa (acid-base dissociation constant) as determined by Morgenthaler ref: ChemMedChem 20072014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID409876Cytotoxicity against human GBM cells at 50 uM after 24 hrs by neutral red uptake assay2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.
AID35967Displacement of [3H]prazosin from calf cerebral cortex alpha-1 adrenergic receptor1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (27.27)18.7374
1990's0 (0.00)18.2507
2000's4 (36.36)29.6817
2010's4 (36.36)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.84 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]